H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

You may not qualify if:

• Investigational Drugs
• Patients who are currently receiving another investigational drug are not eligible.
• Prior treatment with another investigational drug.
• Anti-cancer Agents
• Patients who are currently receiving other anti-cancer agents are not eligible.
• Prior treatment with other anti-cancer agents.
• Patients who have received a live / attenuated vaccine within 30 days of first treatment.
• Patients with evidence of disseminated or leptomeningeal disease.
• Patients with a known disorder that affects their immune system, such as HIV or Hepatitis B or C, or an auto-immune disorder requiring systemic cytotoxic or immunosuppressive therapy are not eligible. Note: Patients that are currently using inhaled, intranasal, ocular, topical or other non-oral or non-IV steroids are not necessarily excluded from the study but need to be discussed with the study chair.
• Patients with a ≥ Grade 2 hypothyroidism due to history of autoimmunity are not eligible. (Note: Hypothyroidism due to previous irradiation or thyroidectomy will not impact eligibility).
• Patients who have received prior solid organ or bone marrow transplantation are not eligible.
• Patients with uncontrolled infection.
• Female patients of childbearing potential must not be pregnant or breast-feeding. Female patients of childbearing potential must have a negative serum or urine pregnancy test prior to the start of therapy (as clinically indicated).